Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Castration-Resistant Prostate Carcinoma: early-phase trial registry
17 of 44 indexed Castration-Resistant Prostate Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #330 of 28,707 conditions by registered trial count.
44 US clinical trials · 17 currently recruiting · #330 of 28,707 conditions by registered trial count
Castration-Resistant Prostate Carcinoma: 44 US clinical trials tracked, 17 recruiting.
Castration-Resistant Prostate Carcinoma is the subject of 44 registered US clinical trials on ClinicalTrials.gov, 17 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 6 of these trials.
Enrollment posture brief
Registry condition castration-resistant-prostate-carcinoma
OPEN 17 | RECR 39% | LATE 2 | EARLY 40 | RANK #330 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Metastatic Urothelial Carcinoma (39% recruiting · 31 trials)
Castration-Resistant Prostate Carcinoma lists 17 open slots (39% of 44 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Castration-Resistant Prostate Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Castration-Resistant Prostate Carcinoma recruits in line with its size-band peers.
17 of 44 indexed trials (38.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Castration-Resistant Prostate Carcinoma trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 6 of 44 trials (13.6%). 21 distinct sponsors appear on at least one study for this condition label.
-
Most Castration-Resistant Prostate Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 39 among the 44 trials that report a genuine target (sentinel values excluded). 36 of those (81.8%) plan for fewer than 100 participants.
-
Castration-Resistant Prostate Carcinoma research is mostly interventional.
43 interventional and 1 observational studies make up this index (97.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
44 total, page 1 of 1
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
SWOG Cancer Research Network
NCT06470243
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Alliance for Clinical Trials in Oncology
NCT06632977
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
NCT06200103
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
University of Washington
NCT06039371
Imaging of Solid Tumors Using 18F-TRX
Rahul Aggarwal
NCT06942104
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
University of Washington
NCT04489719
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
NCT06236139
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
NCT04693377
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
NCT06288113
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
NCT06616155
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
NCT04550494
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
University of Utah
NCT05168618
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Jonsson Comprehensive Cancer Center
NCT05398302
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Vadim S Koshkin
NCT05113537
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
NCT05805371
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
NCT06145633
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
NCT06305598
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
ECOG-ACRIN Cancer Research Group
NCT03419234
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT02703623
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT03217747
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
National Cancer Institute (NCI)
NCT03317392
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
NCT04592237
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
National Cancer Institute (NCI)
NCT02893917
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
National Cancer Institute (NCI)
NCT03517969
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
NCT04388852
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Alliance for Clinical Trials in Oncology
NCT04455750
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Rahul Aggarwal
NCT04471974
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
OHSU Knight Cancer Institute
NCT02312557
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
OHSU Knight Cancer Institute
NCT02522715
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
University of Southern California
NCT03344211
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03218826
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
National Cancer Institute (NCI)
NCT05828082
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
NCT03582475
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
Thomas Hope
NCT04716725
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
City of Hope Medical Center
NCT03873805
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
NCT05689021
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Rashmi Verma, MD
NCT05479578
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
NCT05924672
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
NCT01881867
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
OHSU Knight Cancer Institute
NCT02099864
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT03204812
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
Emory University
NCT03448458
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
University of Washington
NCT02598895
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
NCT05730712
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 25 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Castration-Resistant Prostate Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Castration-Resistant Prostate Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Castration-Resistant Prostate Carcinoma page
44 registered trials, 17 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 17 Castration-Resistant Prostate Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Castration-Resistant Prostate Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Castration-Resistant Prostate Carcinoma condition card totals 44 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.